Do analysts prefer PHXM or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PHXM or SPRC?

PHAXIAM Therapeutics has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A SciSparc $860K 3.45 -$12.18M N/A N/A

Is PHXM or SPRC more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A SciSparc N/A N/A N/A

Do analysts prefer MDCX or SPRC?

Medicus Pharma presently has a consensus price target of $9.00, suggesting a potential upside of 5,805.51%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medicus Pharma is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, MDCX or SPRC?

SciSparc has higher revenue and earnings than Medicus Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.46 N/A SciSparc $860K 3.45 -$12.18M N/A N/A

Is MDCX or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% SciSparc N/A N/A N/A

Does the media prefer MDCX or SPRC?

In the previous week, Medicus Pharma had 3 more articles in the media than SciSparc. MarketBeat recorded 7 mentions for Medicus Pharma and 4 mentions for SciSparc. SciSparc's average media sentiment score of 0.68 beat Medicus Pharma's score of 0.04 indicating that SciSparc is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SciSparc 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ENSC or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ENSC or SPRC?

Ensysce Biosciences has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ensysce Biosciences $5.07M 1.58 -$10.18M -$2.76 N/A SciSparc $860K 3.45 -$12.18M N/A N/A

Do analysts recommend SPRC or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, SPRC or CNSP?

SciSparc has higher revenue and earnings than CNS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.45 -$12.18M N/A N/A CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A

Is SPRC or CNSP more profitable?

SciSparc's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A CNS Pharmaceuticals N/A -204.25% -141.87%

Do analysts rate TRAW or SPRC?

Traws Pharma currently has a consensus target price of $1.00, suggesting a potential upside of 77.56%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, TRAW or SPRC?

Traws Pharma has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Traws Pharma $2.79M 3.10 $9.17M -$1.74 N/A SciSparc $860K 3.45 -$12.18M N/A N/A

Is TRAW or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -23,868.92% -165.52% SciSparc N/A N/A N/A

Does the media prefer TRAW or SPRC?

In the previous week, SciSparc had 1 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for SciSparc and 3 mentions for Traws Pharma. SciSparc's average media sentiment score of 0.68 beat Traws Pharma's score of 0.60 indicating that SciSparc is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SciSparc 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SciSparc (SPRC) Competitors

$5.21 -0.18 (-3.34%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$5.26 +0.05 (+1.06%)

As of 09/25/2026 07:32 PM Eastern

Compare

SPRC vs. PHXM, MDCX, ENSC, CNSP, and TRAW

Should you buy SciSparc stock or one of its competitors? SciSparc's main competitors and comparable companies include PHAXIAM Therapeutics (PHXM), Medicus Pharma (MDCX), Ensysce Biosciences (ENSC), CNS Pharmaceuticals (CNSP), and Traws Pharma (TRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does SciSparc compare to PHAXIAM Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
SciSparc	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, indicating that its stock price is 181% more volatile than the broader market.

In the previous week, SciSparc had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for SciSparc and 0 mentions for PHAXIAM Therapeutics. SciSparc's average media sentiment score of 0.68 beat PHAXIAM Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
SciSparc	Positive

PHAXIAM Therapeutics has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
SciSparc	$860K	3.45	-$12.18M	N/A	N/A

Summary

SciSparc beats PHAXIAM Therapeutics on 6 of the 8 factors compared between the two stocks.

How does SciSparc compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Medicus Pharma presently has a consensus price target of $9.00, suggesting a potential upside of 5,805.51%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medicus Pharma is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market.

SciSparc's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
SciSparc	N/A	N/A	N/A

SciSparc has higher revenue and earnings than Medicus Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
SciSparc	$860K	3.45	-$12.18M	N/A	N/A

In the previous week, Medicus Pharma had 3 more articles in the media than SciSparc. MarketBeat recorded 7 mentions for Medicus Pharma and 4 mentions for SciSparc. SciSparc's average media sentiment score of 0.68 beat Medicus Pharma's score of 0.04 indicating that SciSparc is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
SciSparc	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.1% of SciSparc shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

SciSparc beats Medicus Pharma on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. SciSparc's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
SciSparc	N/A	N/A	N/A

Ensysce Biosciences has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.58	-$10.18M	-$2.76	N/A
SciSparc	$860K	3.45	-$12.18M	N/A	N/A

Ensysce Biosciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market.

In the previous week, SciSparc had 3 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for SciSparc and 1 mentions for Ensysce Biosciences. SciSparc's average media sentiment score of 0.68 beat Ensysce Biosciences' score of 0.60 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Positive
SciSparc	Positive

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

SciSparc beats Ensysce Biosciences on 8 of the 11 factors compared between the two stocks.

How does SciSparc compare to CNS Pharmaceuticals?

SciSparc (NASDAQ:SPRC) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

In the previous week, SciSparc had 3 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 4 mentions for SciSparc and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.79 beat SciSparc's score of 0.68 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SciSparc	Positive
CNS Pharmaceuticals	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SciSparc has higher revenue and earnings than CNS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.45	-$12.18M	N/A	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

SciSparc's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

SciSparc has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Summary

SciSparc beats CNS Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does SciSparc compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Traws Pharma has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, indicating that its stock price is 181% more volatile than the broader market.

SciSparc's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-23,868.92%	-165.52%
SciSparc	N/A	N/A	N/A

In the previous week, SciSparc had 1 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for SciSparc and 3 mentions for Traws Pharma. SciSparc's average media sentiment score of 0.68 beat Traws Pharma's score of 0.60 indicating that SciSparc is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SciSparc	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Traws Pharma has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.10	$9.17M	-$1.74	N/A
SciSparc	$860K	3.45	-$12.18M	N/A	N/A

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 7.6% of Traws Pharma shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Traws Pharma currently has a consensus target price of $1.00, suggesting a potential upside of 77.56%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SciSparc beats Traws Pharma on 7 of the 12 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.05M	$12.54B	$7.27B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	13.51%
P/E Ratio	N/A	789.85	274.42	25.75
Price / Sales	3.45	748.37	618.41	86.14
Price / Cash	N/A	91.64	79.23	52.93
Price / Book	0.40	10.51	10.43	6.30
Net Income	-$12.18M	$2.81B	$3.49B	$359.77M
7 Day Performance	15.52%	-0.96%	-1.25%	-0.23%
1 Month Performance	-22.70%	-3.00%	-4.67%	-3.88%
1 Year Performance	-86.47%	1.05%	15.06%	5.35%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.9056 of 5 stars	$5.21 -3.3%	N/A	-90.5%	$3.05M	$860K	N/A	3	Gap Down
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MDCX Medicus Pharma	2.4794 of 5 stars	$0.16 +2.7%	$9.00 +5,661.8%	-93.9%	$9.61M	N/A	N/A	N/A	Short Interest Increase
ENSC Ensysce Biosciences	1.3987 of 5 stars	$0.45 -0.8%	N/A	-81.8%	$8.79M	$5.07M	N/A	10	News Coverage
CNSP CNS Pharmaceuticals	0.6071 of 5 stars	$5.22 -8.4%	N/A	-41.7%	$8.33M	N/A	N/A	5	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. PHXM, MDCX, ENSC, CNSP, and TRAW

How does SciSparc compare to PHAXIAM Therapeutics?

Summary

How does SciSparc compare to Medicus Pharma?

Summary

How does SciSparc compare to Ensysce Biosciences?

Summary

How does SciSparc compare to CNS Pharmaceuticals?

Summary

How does SciSparc compare to Traws Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. PHXM, MDCX, ENSC, CNSP, and TRAW

How does SciSparc compare to PHAXIAM Therapeutics?

Do institutionals and insiders hold more shares of PHXM or SPRC?

Is PHXM or SPRC more profitable?

Do analysts prefer PHXM or SPRC?

Which has more volatility and risk, PHXM or SPRC?

Does the media refer more to PHXM or SPRC?

Which has better valuation & earnings, PHXM or SPRC?

Summary

How does SciSparc compare to Medicus Pharma?

Do analysts prefer MDCX or SPRC?

Which has more volatility & risk, MDCX or SPRC?

Is MDCX or SPRC more profitable?

Which has preferable valuation and earnings, MDCX or SPRC?

Does the media prefer MDCX or SPRC?

Do insiders & institutionals hold more shares of MDCX or SPRC?

Summary

How does SciSparc compare to Ensysce Biosciences?

Do analysts recommend ENSC or SPRC?

Is ENSC or SPRC more profitable?

Which has preferable earnings and valuation, ENSC or SPRC?

Which has more volatility & risk, ENSC or SPRC?

Does the media refer more to ENSC or SPRC?

Do insiders and institutionals hold more shares of ENSC or SPRC?

Summary

How does SciSparc compare to CNS Pharmaceuticals?

Does the media favor SPRC or CNSP?

Do analysts recommend SPRC or CNSP?

Do institutionals and insiders have more ownership in SPRC or CNSP?

Which has stronger earnings & valuation, SPRC or CNSP?

Is SPRC or CNSP more profitable?

Which has more risk & volatility, SPRC or CNSP?

Summary

How does SciSparc compare to Traws Pharma?

Which has more volatility and risk, TRAW or SPRC?

Is TRAW or SPRC more profitable?

Does the media prefer TRAW or SPRC?

Which has better valuation and earnings, TRAW or SPRC?

Do institutionals & insiders have more ownership in TRAW or SPRC?

Do analysts rate TRAW or SPRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools